How We Do It

Diabetes management in cancer patients

Author and Disclosure Information

 

In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.

Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.


Recommended Reading

Adjuvant AI therapy for breast cancer: 10 years is superior to 5 years
MDedge Hematology and Oncology
Statins improve ovarian cancer survival
MDedge Hematology and Oncology
Glucocorticoids increase risk of S. aureus bacteremia
MDedge Hematology and Oncology
Symptoms linger after ‘successful’ gyn. cancer therapy
MDedge Hematology and Oncology
Racial bias linked with shorter, less-supportive appointments with black patients
MDedge Hematology and Oncology
Quality versus queasy: neurokinin 1 receptor antagonist use in moderately emetogenic chemotherapy
MDedge Hematology and Oncology
The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients
MDedge Hematology and Oncology
Group-based psychosocial services: assessing outpatient oncology needs
MDedge Hematology and Oncology
Nearly 200 practices expected to participate in Oncology Care Model
MDedge Hematology and Oncology
Cisplatin-based chemo may be linked to hearing loss
MDedge Hematology and Oncology